Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.57 |
| ▸ | CTSL | P07711 | 6/20 | 0.56 |
| ▸ | CTSB | P07858 | 3/20 | 0.56 |
| ▸ | CTSS | P25774 | 3/20 | 0.56 |
| ▸ | CTSK | P43235 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14620116 | 0.94 | TACR1 (0.52) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL3827103 | 0.87 | CTSK (0.50) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL7702259 | 0.80 | TRPM8 (0.47) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL9545976 | 0.79 | CTSL (0.69) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL9498759 | 0.79 | TRPM8 (0.47) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL7151822 | 0.79 | ALDH1A1 (0.74) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL329686 | 0.79 | ALDH1A1 (0.74) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL5050481 | 0.78 | CTSK (0.52) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL10802556 | 0.78 | CTSL (0.70) | TACR1CTSLCTSBCTSSCTSK | |
| Hydrochloric Acid SCHEMBL7928050 | 0.78 | ALDH1A1 (0.72) | TACR1CTSLCTSBCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7173039-B2 | Protein kinase inhibitors | THERAVANCE, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173039-B2 | Protein kinase inhibitors | THERAVANCE, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-7037912-B2 | Protein kinase inhibitors | THERAVANCE, INC. (US) | 2006-05-02 | — | — | US | disclosed |
| US-20050261318-A1 | Protein kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC | 2005-11-24 | — | — | US | disclosed |
| US-20040235870-A1 | Enzyme inhibitor contains two or more ligand moieties comprising pyrimidinyl groups covalently linked together by linking groups; keratitis, diabetic retinopathy, angiogenesis, vision defects, ischemia, atherosclerosis,psoriasis, cancer, cirrhosis, diabetes, arthritis, autoimmune disease | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-11-25 | — | — | US | disclosed |
| US-6750241-B2 | Protein kinase inhibitors | THERAVANCE, INC. | 2004-06-15 | — | — | US | disclosed |
| US-20020177600-A1 | Protein kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC | 2002-11-28 | — | — | US | disclosed |
| US-20020002169-A1 | Protein kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC | 2002-01-03 | — | — | US | disclosed |
| WO-2001042243-A2 | PROTEIN KINASE INHIBITORS | ADVANCED MEDICINE, INC. (US) | 2001-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177600-A1 | Protein kinase inhibitors | MAP3K20, MAP3K9, MAP3K6 | TACR1 4265/4885CTSL 3925/4885CTSB 2565/4885 |
| US-20020002169-A1 | Protein kinase inhibitors | MAP3K20, MAP3K6, MAP4K2 | TACR1 4384/4885CTSL 3656/4885CTSB 2453/4885 |
| US-20050261318-A1 | Protein kinase inhibitors | MAP3K20, MAP3K6, MAP4K2 | TACR1 4384/4885CTSL 3656/4885CTSB 2453/4885 |
| US-20040235870-A1 | Enzyme inhibitor contains two or more ligand moieties comprising pyrimidinyl groups covalently linked together by linking groups; keratitis, diabetic retinopathy, angiogenesis, vision defects, ischemia, atherosclerosis,psoriasis, cancer, cirrhosis, diabetes, arthritis, autoimmune disease | UACA, PRKDC, CDK2 | TACR1 4254/4885CTSL 1771/4885CTSB 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.